Biogen (BIIB) 10-K Summary — Year Ended Dec 31, 2025
Biogen Inc. filed its annual report for the fiscal year. The company reported a slight increase in revenue after two years of decline, and its liquidity position strengthened through a debt issuance and acquisition.
Key takeaway
Year ended Dec 31, 2025 · FY2025 10-K
Biogen Inc. filed its annual report for the fiscal year. The company reported a slight increase in revenue after two years of decline, and its liquidity position strengthened through a debt issuance and acquisition.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$9.9B
Revenue reported for the fiscal year.
Operating income
n/a
Income from operations reported for the year.
Net income
$1.3B
Net income reported for the year.
Operating cash flow
$2.2B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2022 | $10.2B | -7.4% |
| Dec 31, 2023 | $9.8B | -3.3% |
| Dec 31, 2024 | $9.7B | -1.6% |
| Dec 31, 2025 | $9.9B | +2.2% |
Business overview
Biogen is a biotechnology company focused on neurological diseases, as indicated by its acquisition of Alcyone Therapeutics, a clinical-stage firm developing a device for intrathecal delivery of therapies including its own product SPINRAZA. The company operates in the CNS therapeutics space.
Financial performance
Revenue increased modestly compared to the prior year, reversing a trend of declining sales over the previous two years. Net income and operating cash flow were reported, though operating cash flow decreased from the prior year due to higher tax payments.
Material risks
The supplied filing context does not include detailed risk factor descriptions. Therefore, no specific material risks can be identified from the available information.
Liquidity and capital
The company ended the period with a strong cash position, having issued new senior notes and redeemed an existing debt. It also used cash to acquire Alcyone Therapeutics for an upfront payment.
What to watch
The progress of the Alcyone Therapeutics acquisition, particularly the development of ThecaFlex DRx, should be monitored in the next filing.